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Magdi H. Yacoub, MDBiology is complex, messy and richly various
like real life
—Peter Medawar (1)SEE PAGE 877L ife imparts almost magical powers to the indi-vidual, organ, or tissue. Heart valves are noexception (2). It is now well established that
the living valve performs extremely sophisticated
functions that are dependent on the viability and
interaction of its component parts. These functions
including the capacity to adapt and grow, translate
directly into clinically relevant end points such as
survival and quality of life. These facts have stimu-
lated the search for a living heart valve substitute.
To date, the only clinical example of a living valve
substitute is the Ross operation, which unfortu-
nately is grossly underutilized, due to a variety of
reasons, including the perceived complexity of the
operative procedure (3). This highlights the need
for developing a simple, off-the-shelf, living valve
substitute.
To that end, several strategies have been used
(4,5). Success of these efforts depends on reproducing
or emulating the continuing cross talk between the
extracellular matrix and speciﬁc cellular components,
which characterize a living valve (2). In the past, the
extracellular matrix (ECM) was thought to consist of
inert substances, secreted by the cells with the sole
function of acting as cement surrounding the cells
and inﬂuencing the physical properties of the partic-
ular tissue. This view has been challenged by the
ﬁndings that the ECM is metabolically active and can
act as major regulator of cellular functions, including*Editorials published in the Journal of the American College of Cardiology
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of this paper to disclose.morphogenesis. These concepts are being explored in
tissue engineering, with varying degrees of success
(6,7). In this issue of the Journal, the report by Zafar
et al. (8) is a welcome addition to the literature. The
authors thoroughly investigated the use of an
unstented tube scaffold made of an acellular scaffold
manufactured from small intestinal submucosa, Cor-
Matrix (CorMatrix Cardiovascular, Roswell, Georgia),
for tricuspid valve replacement in a growing sheep
model. The capacity of the valve to grow was docu-
mented over a period of 8 months. In addition,
detailed histological examination, 8 months after
implantation, showed what appeared to be almost
complete replacement of the noncoapting part of the
valve by host tissue, having a similar appearance to
native cusp tissue. This excellent study represents a
signiﬁcant step towards the goal of producing a living
valve substitute and raises several related issues to
choice of material, valve design, and host responses.CHOICE OF A SMART SCAFFOLD MATERIAL
The ideal scaffold material should be resorbable,
nonimmunogenic, and capable of attracting, housing,
and instructing cells to produce the particular
phenotype. It should also reproduce the mechanical
properties of the native valve, both in the short and
long term. Two major types of scaffolds are currently
being considered, the ﬁrst are natural bioscaffolds
prepared from decellularized non–cross-linked ECM,
such as the one used in the report by Zafar et al.
(8), and decellularized valves and whole organs (9).
Other types of bioscaffolds are derived from amniotic
membrane (10), or alginate manufactured from sea
weed (11). The nature of the cytokines and growth
factors secreted by bioscaffolds is being actively
studied, but remains largely unknown. This applies to
both allogenic and xenogeneic decellularized valves.
In addition, removal of all cellular material does not
render the matrix totally nonimmunogenic. Several
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890components of the ECM such as collagen and elastin
can be immunogenic, and could require speciﬁc
processing. Interestingly, some biomaterials such as
small intestinal submucosa stimulate TH2 response
locally without affecting the host immune response
to viruses (12).
The second type of intelligent scaffolds consist of
synthetic polymers decorated by speciﬁc molecules
(13), designed to enhance their capacity to attract and
instruct the host cells, either from local or distant
sources, and induce them to transdifferentiate to
a tissue-speciﬁc phenotype (Figure 1). One major
advantage of these materials is the fact that they
can reproduce the anisotropic properties of the
valve (14).
VALVE DESIGN
Valve design contributes to several important func-
tions of the speciﬁc valve. These include optimal
hemodynamic performance (15), smooth opening
and closing characteristics, passive dynamism (2),
and importantly, inﬂuencing ventricular function and
coronary ﬂow, in the case of the aortic valve. The
tubular design used by Zafar et al. (8) have several
advantages, which include being stent-less, haveFIGURE 1 Some Approaches for Selective Enhancement of Surface C
Some approaches for selective enhancement of surface characteristics
and controlled release of regulatory growth factors. Reprinted with pe
aspartic acid.wide inlet and outlet oriﬁces, and attach the annulus
to the ventricular myocardium, thus enhancing
the longitudinal ventricular function. However, any
tubular design is subject to Poiseuille’s law and
therefore increases the resistance to ﬂow. In addition,
it lacks the intercordal spaces. The fact that the
coapting part of the valve substitute was not replaced
by the host tissue is intriguing.
During valvulogenesisis in the embryo, there is
close interaction between hemodynamics and valve
development (16). The role of such interaction in




Following insertion, all tissue valves develop an
intimate type of interaction with the host (17). This is
contributed to by many factors, which include the
composition of the valve, the methods of processing,
the technique of insertion, and importantly, by the
genetic and epigenetic characteristics of the host.
This should stimulate the development of a tailored,
personalized approach to the use of tissue valves in
the future.haracteristics of Hydrogel Scaffolds
of hydrogel scaffolds toward increasing surface-cells attachment
rmission from El-Sherbiny and Yacoub (13). RGD ¼ arginine–glycine–
J A C C V O L . 6 6 , N O . 8 , 2 0 1 5 Yacoub
A U G U S T 2 5 , 2 0 1 5 : 8 8 9 – 9 1 In Search of Living Valve Substitutes
891CONCLUSIONS AND FUTURE DIRECTIONS
The report of Zafar et al. (8) represents an important
step towards the Holy Grail of developing a tissue-
engineered living heart valve. It also highlights
several issues that need to be addressed before this
becomes a clinical reality. None of these issues is
insuperable, and should be solved in the near future.This will enable valve replacement to achieve its full
potential, particularly in children.
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